Drug Profile
Ziritaxestat - Gilead Sciences
Alternative Names: G-451990; GLPG 1690Latest Information Update: 15 Feb 2022
Price :
$50
*
At a glance
- Originator Galapagos NV
- Class Anti-inflammatories; Antifibrotics; Azetidines; Imidazoles; Nitriles; Piperazines; Pyridines; Small molecules; Thiazoles
- Mechanism of Action ENPP2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease; Idiopathic pulmonary fibrosis; Systemic scleroderma
Most Recent Events
- 05 Sep 2021 Pharmacodynamics data from a preclinical trial in Idiopathic pulmonary fibrosis presented at the 31st Annual Congress of the European Respiratory Society (ERS-2021)
- 25 Feb 2021 CTP Push 293466 - info was already covered from MR 9315594
- 10 Feb 2021 Discontinued - Phase-I for Idiopathic pulmonary fibrosis (In volunteers) in Belgium (PO, capsule)